Description

Buy Wegovy (Semaglutide) Weekly Injection for Weight Management

Wegovy is a weight loss injection that is taken weekly and contains 4 doses. It contains the active ingredient semaglutide, which works to make you feel fuller for longer by mimicking a hormone that is usually released after eating. You can lose an average of 21% of your starting weight by 72 weeks when taking Wegovy 7.2mg alongside healthy lifestyle changes to your diet and exercise routines. As a result, Wegovy can also improve heart health and help prevent cardiovascular disease.

Wegovy is available as part of our weight loss service. We provide:

• free advice, support & aftercare from our US doctors
• hassle-free online consultation (no need to see a doctor in person)
• nutritional guidance from our in-house team, weight loss trackers, and diaries to keep you on track
• Convenient collection at an RELIABLE PHARMACY USA — same day if approved before 3pm, next day after — or discreet delivery to your address
• treatment with no hidden fees or additional costs
• free needles for your injections, with sharps bins available on request

Wegovy Pill FDA Approval

The FDA approved Wegovy tablets on December 22, 2025, following positive results from the OASIS 4 phase 3 clinical trial (NCT05564117).

Who can use the Wegovy pill and injection?

Wegovy Injections are used for:

• Long-term weight loss and weight management in:

• • adults with obesity.
  • adults who are overweight and  have a weight-related medical problem (e.g., blood pressure, type 2 diabetes, or high cholesterol)

• To reduce the risk of major adverse CV events in:

• • adults with established cardiovascular disease who have obesity or are overweight.

Wegovy injection can be used for:

• Long-term weight loss and weight management in:

• • adults and patients over 12 years old with obesity, or
  • adults who are overweight and have a weight-related medical problem (e.g., blood pressure, type 2 diabetes, or high cholesterol)

• Reduce the risk of major cardiovascular events such as cardiovascular death, non-fatal myocardial infarction, or nonfatal stroke in:
  • adults with established cardiovascular disease and either obesity or overweight.

• Noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in:
  • Patients with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults.
  • This is an accelerated approval based on the improvement of MASH and fibrosis. Continued approval for this indication is dependent on confirmation of clinical benefit in a clinical trial.
  • MASH was formerly known as nonalcoholic steatohepatitis (NASH).